68Ga-NeoBOMB1

N/A

Report date: 2025/12/10 17:22:08
NME

Base Information

Drug Name68Ga-NeoBOMB1
Drug Alias Name67Ga-NeoBOMB168Ga-NeoBOMB1[68Ga]Ga-NeoB68Ga-NeoB
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5] 
Mechanisms of ActionBombesin receptor antagonistsIonising radiation emittersNeuropeptide receptor antagonists +[5] 
TargetsNeuropeptide receptorGastrin-releasing peptideBombesin receptor +[4] 
Therapy Area/IndicationsMetastatic breast cancerProstatic NeoplasmsSmall Cell Lung Carcinoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustriaFranceMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesErasmus Universiteit RotterdamNational Center For Scientific Research Demokritos
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesAdvanced Accelerator Applications SaMedical University Of Innsbruck
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[5] 

Other Information

ATC CodeN/A
Related LinksN/A